Insulet Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Insulet Corporation sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials 3 currently recruiting 12 completed top decile by trial count

Insulet Corporation: 16 sponsored US clinical trials, 3 recruiting.

Insulet Corporation sponsors 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 12 completed. The most-studied condition in this pipeline is Type 1 Diabetes, with 2 trials.

Top-decile sponsor footprint

Insulet Corporation ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

16 total, page 1 of 1

RECRUITING NA

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

NCT07579702

RECRUITING NA

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

NCT07521475

RECRUITING

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

NCT06144554

ACTIVE NOT RECRUITING NA

An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

NCT07276776

COMPLETED NA

Simplified Onboarding in Adults With Type 2 Diabetes

NCT07070830

COMPLETED NA

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

NCT06865989

COMPLETED NA

OP5-005 Using Omnipod 5 in Adults With Type 2

NCT05815342

COMPLETED NA

Omnipod 5 System Compared to Pump Therapy

NCT05409131

COMPLETED NA

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NCT04617795

COMPLETED NA

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

NCT04476472

COMPLETED NA

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

NCT04320069

COMPLETED NA

Pivotal Omnipod Horizon™ Automated Glucose Control System

NCT04196140

COMPLETED NA

Prepivotal Omnipod Horizon™ Automated Glucose Control System

NCT04176731

COMPLETED NA

Insulet Artificial Pancreas Free-Living IDE3

NCT03216460

COMPLETED NA

Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)

NCT03064906

COMPLETED NA

Insulet Artificial Pancreas Early Feasibility Study

NCT02897557

What is open in the Insulet Corporation pipeline

3 recruiting of 16 indexed (19% open); 12 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Type 1 Diabetes (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Insulet Corporation: open-pipeline peers nationwide

Peers matched on 16 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

Insulet Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share Insulet CorporationAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera PharmaceuticalsEyePoint PharmaceuticalsHebrew SeniorLifeUniversity of California, DavisMedical University of South Carolina
Insulet Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Insulet Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this Insulet Corporation page

16 registered trials is a research-attention snapshot, not an endorsement of Insulet Corporation or any single study.

  • 3 of Insulet Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes is the condition Insulet Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Insulet Corporation pipeline card: 16 registered trials from official public datasets.Report a data error.